Bladder Cancer-related microRNAs With In Vivo Efficacy in Preclinical Models.

Cancer Diagn Progn

Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.

Published: July 2021

Progressive and metastatic bladder cancer remain difficult to treat. In this review, we critique seven up-regulated and 25 down-regulated microRNAs in order to identify new therapeutic entities and corresponding targets. These microRNAs were selected with respect to their efficacy in bladder cancer-related preclinical in vivo models. MicroRNAs and related targets interfering with chemoresistance, cell-cycle, signaling, apoptosis, autophagy, transcription factor modulation, epigenetic modification and metabolism are described. In addition, we highlight microRNAs targeting transmembrane receptors and secreted factors. We discuss druggability issues for the identified targets.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988954PMC
http://dx.doi.org/10.21873/cdp.10033DOI Listing

Publication Analysis

Top Keywords

bladder cancer-related
8
micrornas
5
cancer-related micrornas
4
micrornas vivo
4
vivo efficacy
4
efficacy preclinical
4
preclinical models
4
models progressive
4
progressive metastatic
4
metastatic bladder
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!